Your browser doesn't support javascript.
loading
Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain.
Mao, Jie; Eom, Gi-Deok; Yoon, Keon-Woong; Kim, Min-Ju; Chu, Ki-Back; Kang, Hae-Ji; Quan, Fu-Shi.
Afiliação
  • Mao J; Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Eom GD; Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Yoon KW; Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Kim MJ; Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Chu KB; Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Kang HJ; Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, GA 30303, USA.
  • Quan FS; Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea.
Nanomedicine (Lond) ; 19(9): 741-754, 2024 04.
Article em En | MEDLINE | ID: mdl-38390688
ABSTRACT

Aims:

To develop an effective universal vaccine against antigenically different influenza viruses. Materials &

methods:

We generated influenza virus-like particles (VLPs) expressing the H1 and H3 antigens with or without M2e5x. VLP-induced immune responses and crossprotection against H1N1, H3N2 or H5N1 viruses were assessed to evaluate their protective efficacy.

Results:

H1H3M2e5x immunization elicited higher crossreactive IgG antibodies than H1H3 VLPs. Upon challenge, both VLPs enhanced lung IgG, IgA and germinal center B-cell responses compared with control. While these VLPs conferred protection, H1H3M2e5x showed greater lung viral load reduction than H1H3 VLPs with minimal body weight loss.

Conclusion:

Utilizing VLPs containing dual-hemagglutinin, along with M2e5x, can be a vaccination strategy for inducing crossprotection against influenza A viruses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por Orthomyxoviridae / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Virus da Influenza A Subtipo H5N1 Limite: Animals / Humans Idioma: En Revista: Nanomedicine (Lond) Ano de publicação: 2024 Tipo de documento: Article País de publicação: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por Orthomyxoviridae / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Virus da Influenza A Subtipo H5N1 Limite: Animals / Humans Idioma: En Revista: Nanomedicine (Lond) Ano de publicação: 2024 Tipo de documento: Article País de publicação: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM